Update shared on24 Sep 2025
Fair value Increased 3.12%Analysts have raised Harrow's price target to $61.98, reflecting optimism about upcoming biosimilar launches, a strengthening market position in eye care, and expectations for upside to current revenue guidance.
Analyst Commentary
- Introduction of ophthalmic biosimilars Byooviz and Opuviz expected to materially contribute to revenue starting in 2026.
- Bullish analysts view current revenue guidance as potentially conservative, especially given strong Q2 setup and momentum.
- Growing perception within the eye-care industry that Harrow is becoming a key one-stop player boosts confidence in sustained market relevance.
- Management’s commercial strategies around biosimilars remain to be detailed, with anticipation for further clarification at the upcoming analyst day.
- Short-term VEVYE sales irregularities attributed to transitions in patient out-of-pocket costs post-launch, with normalization expected under new pricing program.
What's in the News
- Harrow replaced Crowe LLP with Deloitte & Touche LLP as its independent registered public accounting firm.
- The company's Board adopted amended and restated bylaws, updating officer roles and aligning governance practices.
- Harrow affirmed its 2025 revenue guidance of over $280 million and confirmed it's on track to meet this goal.
- The company held an Analyst/Investor Day.
Valuation Changes
Summary of Valuation Changes for Harrow
- The Consensus Analyst Price Target has risen slightly from $60.10 to $61.98.
- The Future P/E for Harrow has risen slightly from 14.35x to 14.65x.
- The Consensus Revenue Growth forecasts for Harrow remained effectively unchanged, moving only marginally from 37.1% per annum to 37.6% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.